-
Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug
Tuesday, August 20, 2019 - 8:59am | 387Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) are tanking Tuesday morning as a binary event turned up a negative outcome for the company. What Happened Sarepta announced Monday after the market close the FDA issued a complete response letter for its NDA seeking accelerated approval for...
